ArticleFrontiers in veterinary science2026
Development of a monoclonal antibody-based competitive ELISA for serological detection of lumpy skin disease virus.
Article in Frontiers in veterinary science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lumpy skin disease (LSD) is a transboundary viral disease of cattle caused by lumpy skin disease virus (LSDV), resulting in substantial economic losses and posing a serious threat to the global cattle industry and international trade. Effective serological surveillance is essential for disease control and for evaluating vaccination programs. However, most currently available serological assays rely on a limited number of viral structural proteins as antigens, which restricts antigen diversity and may limit their applicability, particularly in the development of DIVA-compatible diagnostic strategies, highlighting the need to explore alternative diagnostic targets. In this study, we developed a monoclonal antibody-based competitive enzyme-linked immunosorbent assay (cELISA) targeting LSDV001, a highly conserved protein among Capripoxvirus species. Although LSDV001 is not a classical structural protein, it was consistently detected in purified virions and specifically recognized by antibodies in bovine immune sera, supporting its relevance as a serological target. A high-affinity monoclonal antibody (8E5) was generated and used to establish the cELISA. Receiver-operating characteristic (ROC) curve analysis showed that the sensitivity and specificity of the assay were 96.83 and 98.00%. The assay showed good reproducibility, no detectable cross-reactivity with other bovine pathogens, and strong agreement with the virus neutralization test (VNT). Further evaluation using 148 field serum samples demonstrated an overall concordance rate of 95.3% with VNT, with a Cohen's kappa coefficient of 0.913, indicating substantial agreement between the two methods. Collectively, this LSDV001-based cELISA provides a sensitive and practical tool for large-scale serological surveillance and evaluation of vaccination responses against LSD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.